• Cephalosporin Drugs Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Cephalosporin Drugs Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Increasing Drug Approvals and R&D Activities is expected to Drive Growth of the Cephalosporin
Drugs Market
Approvals and launch of novel products is expected to be a major factor driving the global
cephalosporin drugs market growth over the forecast period. For instance, in June 2019, Merck
& Co. announced that the U.S. Food and Drug Administration (FDA) approved its supplemental
New Drug Application (sNDA) for the use of ZERBAXA (ceftolozane and tazobactam) for the
treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and
ventilator-associated bacterial pneumonia.
Increasing research and development activities has spurred growth of the cephalosporin drugs
market. For instance, in November 2017, B. Braun Medical Inc. initiated a clinical trial of
Cefazolin infusion evaluating the safety of 1 g and 2 g of Cefazolin in pediatric subjects. The
study is in phase 4 and is expected to be completed in July 2019. Therefore, increasing
research on cephalosporin drugs is expected to create a favorable environment for the
cephalosporin drugs market growth over the forecast period.
Market Dynamics
Increasing prevalence of respiratory tract infections worldwide is expected to boost the
cephalosporin drugs market growth. For instance, according to the report of The Global Impact
of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the
leading causes of death, accounting for over 4 million fatalities, annually. Furthermore,
pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the
deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause
of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015.